Telerehabilitation for frail cirrhotic patients awaiting liver transplant: A safe, effective strategy to improve outcomes

Table 2 Cross-analysis of clinical and demographic characteristics between adherent and non-adherent patients, n (%)

Variable	Class (n)	Group		P value
		Non-adherents	Adherent
Sex	Female (27)	22 (55)	5 (29.41)	0.087
	Male (30)	18 (45)	12 (70.59)
Blood type1	A (18)	9 (23.07)	9 (52.94)	0.380
	B (8)	6 (15.38)	2 (11.76)
	O (28)	22 (56.41)	6 (35.29)
	AB (2)	2 (5.13)	0 (0)
Aetiology of liver disease1	Cirrhosis due to alcohol (16)	11 (27.5)	5 (29.41)	0.239
	Hepatitis C virus cirrhosis (4)	3 (7.5)	1 (5.88)
	Primary sclerosing cholangitis (2)	2 (5)	0 (0)
	Retransplant (10)	8 (20)	2 (11.76)
	Autoimmune hepatitis (4)	4 (10)	0 (0)
	Cryptogenic cirrhosis (7)	4 (10)	3 (17.65)
	MASH (7)	6 (15)	1 (5.88)
	Other (7)	2 (5)	5 (29.41)
Encephalopathy	No (35)	22 (55)	13 (76.47)	0.152
	Yes (22)	18 (45)	4 (23.53)
Ascites	No (19)	12 (30)	7 (41.18)	0.567
	Yes (38)	28 (70)	10 (58.82)
HCC1	No (49)	34 (85)	15 (88.24)	0.999
	Yes (8)	6 (15)	2 (11.76)
UGIB1	No (48)	33 (82.5)	15 (88.24)	0.710
	Yes (9)	7 (17.5)	2 (11.76)
Previous surgery	No (20)	10 (25)	10 (58.82)	0.200
	Yes (37)	30 (75)	7 (41.18)
Refractory ascites	No (39)	27 (67.5)	12 (70.59)	0.999
	Yes (18)	13 (32.5)	5 (29.41)
Portal vein thrombosis1	No (54)	38 (95)	16 (94.12)	0.999
	Yes (3)	2 (5)	1 (5.88)
	Yes (1)	1 (2.5)	0 (0)
	Yes (20)	14 (35)	6 (35.29)
Outcome1	Contraindicated transplantation (4)	4 (10)	0 (0)	0.663
	Inactive on the transplant list (1)	1 (2.5)	0 (0)
	Active on the transplant list (13)	9 (22.5)	4 (23.53)
	Death – before transplantation (6)	5 (12.5)	1 (5.88)
	Transplant performed (33)	21 (52.5)	12 (70.59)

¹Fisher's exact test.

χ² test or Fisher's exact test (significance levels of 5%). The table presents a comparative analysis of variables including sex, blood type, liver disease etiology, clinical complications, transplant outcomes, and other relevant clinical parameters between groups. MASH: Metabolic dysfunction-associated steatohepatitis; HCC: Hepatocellular carcinoma; UGIB: Upper gastrointestinal bleeding.